Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Boxer Capital, LLC

Q2 2023 · 13F-HR

Boxer Capital, LLCholdings as filed

Filed 2023-08-14 · accession 0000895345-23-000469

$2.2M
Reported value
79
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
75615P103Reata Pharmaceuticals Inc$145,8036.76%1,430,004CommonSOLE
03753U106APLSUSDApellis Pharmaceuticals Inc$143,5746.66%1,576,000CommonSOLE
76155X100RVMDRevolution Medicines Inc$125,3045.81%4,684,264CommonSOLE
90240B106TYRATyra Biosciences Inc$109,8165.09%6,448,359CommonSOLE
85205L107SWTXUSDSpringworks Therapeutics Inc$89,7134.16%3,421,541CommonSOLE
07725L102ONCBeiGene Ltd$89,1504.13%500,000CommonSOLE
00973Y108AKROAkero Therapeutics Inc$78,2873.63%1,676,733CommonSOLE
60468T105MRTXEURMirati Therapeutics Inc$72,2603.35%2,000,000CommonSOLE
803607100SRPTSarepta Therapeutics Inc$68,7123.19%600,000CommonSOLE
23282W605CYTKCytokinetics Inc$68,5023.18%2,100,000CommonSOLE
45253H101IMGNEURImmunoGen Inc$55,8742.59%2,961,000CommonSOLE
48576A100Karuna Therapeutics Inc$54,2132.51%250,000CommonSOLE
45166A102IDYAIdeaya Biosciences Inc$51,7662.40%2,202,812CommonSOLE
78667J108SG7Sage Therapeutics Inc$51,4402.39%1,094,000CommonSOLE
670703107NUVLNuvalent Inc$51,0342.37%1,210,192CommonSOLE
N5749R1002GHMerus N V$50,0272.32%1,900,000CommonSOLE
03237H101AMLXAmylyx Pharmaceuticals Inc$44,9522.08%2,084,000CommonSOLE
52490G102LEGNLegend Biotech Corp$41,4181.92%600,000CommonSOLE
282559103ETNBGBP89Bio Inc$39,7951.85%2,100,000CommonSOLE
03969F109RCUSArcus Biosciences Inc$32,5411.51%1,602,200CommonSOLE
46583P102Iveric Bio Inc$32,4561.51%825,000CommonSOLE
92686J106VKTXViking Therapeutics Inc$32,4201.50%2,000,000CommonSOLE
04016X101ARGXArgenx SE$29,2301.36%75,000CommonSOLE
03152W109AM6Amicus Therapeutics Inc$29,2021.35%2,325,000CommonSOLE
77313F106RCKTRocket Pharmaceuticals Inc$29,1301.35%1,466,051CommonSOLE
05464T104AXSMAxsome Therapeutics Inc$28,7441.33%400,000CommonSOLE
46565G1045E7iTeos Therapeutics Inc$28,5201.32%2,154,058CommonSOLE
92332V107VTYXUSDVentyx Biosciences Inc$27,8801.29%850,000CommonSOLE
032724106ANABAnaptysBio Inc$26,4421.23%1,300,000CommonSOLE
462260100IOVAIovance Biotherapeutics Inc$26,0841.21%3,705,133CommonSOLE
87583X109TNGXTango Therapeutics Inc$23,6501.10%7,123,642CommonSOLE
98420N105XENEXenon Pharmaceuticals Inc$23,1001.07%600,000CommonSOLE
558868105MDGLMadrigal Pharmaceuticals Inc$23,1001.07%100,000CommonSOLE
75943R102RLAYRelay Therapeutics Inc$22,8481.06%1,819,132CommonSOLE
730541109Point Biopharma Global Inc$22,6501.05%2,500,000CommonSOLE
30161Q104EXELExelixis Inc$21,9771.02%1,150,000CommonSOLE
G72800108PRTAProthena Corp PLC$20,4840.95%300,000CommonSOLE
69353Y103PMVPPMV Pharmaceuticals Inc$19,8050.92%3,163,795CommonSOLE
483497103KALVKalvista Pharmaceuticals Inc$14,8500.69%1,650,000CommonSOLE
29337E102ELVNEnliven Therapeutics Inc$14,5040.67%710,644CommonSOLE
23954D109DAWNGBXDay One Biopharmaceuticals I$14,2080.66%1,189,943CommonSOLE
68622P109ORICOric Pharmaceuticals Inc$13,4450.62%1,732,571CommonSOLE
98943L107ZNTLZentalis Pharmaceuticals Inc$12,6950.59%450,000CommonSOLE
05370A108RNAGBPAvidity Biosciences Inc$12,4360.58%1,121,327CommonSOLE
67080M103NRIXNurix Therapeutics Inc$12,2370.57%1,224,892CommonSOLE
230031106CGEMCullinan Oncology Inc$11,5570.54%1,074,082CommonSOLE
74065P101PRLDPrelude Therapeutics Inc$11,2280.52%2,495,018CommonSOLE
09203E105BDTXBlack Diamond Therapeutics I$10,1750.47%2,014,858CommonSOLE
374163103GERNGeron Corp$9,6300.45%3,000,000CommonSOLE
04351P101ASNDUSDAscendis Pharma A/S$8,4790.39%95,000CommonSOLE
152309100CNTACentessa Pharmaceuticals PLC$7,7450.36%1,251,137CommonSOLE
12674W109CABACabaletta Bio Inc$6,9710.32%540,000CommonSOLE
19240Q201COGTCogent Biosciences Inc$6,2160.29%525,000CommonSOLE
254604101IRONDisc Medicine Inc$5,7720.27%130,000CommonSOLE
75382E109Rapt Therapeutics Inc$5,6100.26%300,000CommonSOLE
901384107TSVT*2Seventy Bio Inc$4,6540.22%459,836CommonSOLE
38341P102GOSSGossamer Bio Inc$4,0040.19%3,336,928CommonSOLE
816212104SELBUSDSelecta Biosciences Inc$3,6780.17%3,284,072CommonSOLE
59045L106Mersana Therapeutics Inc$3,2900.15%1,000,000CommonSOLE
88369M101Theseus Pharmaceuticals Inc$3,2660.15%350,000CommonSOLE
589492107MREOMereo Biopharma Group PLC$2,9700.14%2,250,000CommonSOLE
23306J101DBV Technologies S A$2,7550.13%1,450,000CommonSOLE
88427A107Third Harmonic Bio Inc$2,7440.13%570,417CommonSOLE
31189P102FATEFate Therapeutics Inc$2,3800.11%500,000CommonSOLE
04965G109BCELUSDAtreca Inc$2,1580.10%2,202,333CommonSOLE
09077B104BCABGBPBioAtla Inc$2,0590.10%686,347CommonSOLE
59935V107MISTMilestone Pharmaceuticals In$1,9920.09%698,861CommonSOLE
26886C107EQRx Inc$1,8600.09%1,000,000CommonSOLE
68572M106OBIOOrchestra Biomed Hldgs Inc$1,7500.08%250,000CommonSOLE
49705R105KNTEUSDKinnate Biopharma Inc$1,4880.07%491,000CommonSOLE
75082Q105Rain Oncology Inc$1,3830.06%1,152,212CommonSOLE
62921N105NGMUSDNGM Biopharmaceuticals Inc$1,2950.06%500,000CommonSOLE
55279B202MEI Pharma Inc$9580.04%145,654CommonSOLE
98973P101Alaunos Therapeutics Inc$7650.04%1,500,000CommonSOLE
74365U107TARAProtara Therapeutics Inc$5000.02%209,227CommonSOLE
92536C103VERUEURVeru Inc$4130.02%347,300CommonSOLE
079481404Bellicum Pharmaceuticals Inc$1670.01%450,000CommonSOLE
67080N119NUVB/WSNuvation Bio Inc$440.00%266,666CommonSOLE
86889P117SRZNWSurrozen Inc$40.00%66,666CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.